Histone deacetylase inhibitor LBH589 radiosensitizes non-small cell lung cancer by inhibiting DNA repair

被引：0
|
作者：
Cuneo, K. C. [1 ]
Fu, A. [1 ]
Hallahan, D. E. [1 ]
Geng, L. [1 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37212 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 66卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2006.07.314
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049
引用
收藏
页码：S158 / S158
页数：1
相关论文
共 50 条
  • [21] OTU deubiquitinase 4 is silenced and radiosensitizes non-small cell lung cancer cells via inhibiting DNA repair
    Zhiqiang Wu
    Minghan Qiu
    Yu Guo
    Jinlin Zhao
    Zhuang Liu
    Hui Wang
    Maobin Meng
    Zhiyong Yuan
    Zeyun Mi
    Cancer Cell International, 19
  • [22] The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Sanchez, Eric
    Shen, Jing
    Steinberg, Jeffrey
    Li, Mingjie
    Wang, Cathy
    Bonavida, Benjamin
    Chen, Haiming
    Li, Zhi-Wei
    Berenson, James R.
    LEUKEMIA RESEARCH, 2011, 35 (03) : 373 - 379
  • [23] Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer
    Lewis, L.
    Frank, R.
    Dandamudi, U. B.
    Gallagher, J.
    Zhao, L.
    Woo, M.
    Hirawat, S.
    Shapiro, G. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Histone deacetylase inhibitor (HDACi) LBH589 interference with androgen receptor expression transcriptional activity in prostate cancer cells.
    Thelen, Paul
    Ringert, Rolf-Hermann
    Strauss, Arne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in low-grade neuroendocrine tumors
    Rajguru, Saurabh
    Lubner, Sam Joseph
    Mulkerin, Daniel
    Schelman, William R.
    Winterle, Natalie
    Holen, Kyle D.
    Leverson, Glen
    Chen, Herbert
    LoConte, Noelle K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Munster, P. N.
    Petrou, P.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Rugo, H. S.
    Chan, J. K.
    Thurn, K. T.
    Reinert, A.
    Daud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
    Symanowski, James
    Vogelzang, Nicholas
    Zawel, Leigh
    Atadja, Petet
    Pass, Harvey
    Sharma, Sunil
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 149 - 160
  • [28] The novel histone deacertylase inhibitor, LBH589 radiosensitizes human cancer cell lines potentially through the attenuation of EGFR or her-2 signaling.
    Kim, IA
    Choi, YJ
    Kim, JS
    Kim, IH
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9007S - 9007S
  • [29] The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
    Crisanti, M. Cecilia
    Wallace, Africa F.
    Kapoor, Veena
    Vandermeers, Fabian
    Dowling, Melissa L.
    Pereira, Luana P.
    Coleman, Kara
    Campling, Barbara G.
    Fridlender, Zvi G.
    Kao, Gary D.
    Albelda, Steven M.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (08) : 2221 - 2231
  • [30] The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
    Vallo, Stefan
    Mani, Jens
    Stastny, Matthias
    Makarevic, Jasmina
    Juengel, Eva
    Tsaur, Igor
    Bartsch, Georg
    Haferkamp, Axel
    Blaheta, Roman A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 265 - 272
12345